[HTML][HTML] Piperacillin concentration in relation to therapeutic range in critically ill patients–a prospective observational study

J Zander, G Döbbeler, D Nagel, B Maier, C Scharf… - Critical Care, 2016 - Springer
J Zander, G Döbbeler, D Nagel, B Maier, C Scharf, M Huseyn-Zada, J Jung, L Frey…
Critical Care, 2016Springer
Background Piperacillin levels after standard dosing have been shown frequently to be
subtherapeutic, especially when renal clearance was augmented. Here, we aimed to
determine if piperacillin was in its therapeutic range in a typically heterogeneous intensive
care unit patient group, and also to describe target attainment dependent on daily dosage,
creatinine clearance, and renal replacement therapy (RRT). Methods Sixty patients with
severe infections were included in this monocentric prospective observational study …
Background
Piperacillin levels after standard dosing have been shown frequently to be subtherapeutic, especially when renal clearance was augmented. Here, we aimed to determine if piperacillin was in its therapeutic range in a typically heterogeneous intensive care unit patient group, and also to describe target attainment dependent on daily dosage, creatinine clearance, and renal replacement therapy (RRT).
Methods
Sixty patients with severe infections were included in this monocentric prospective observational study. Patients received 4.5 g of piperacillin-tazobactam two to three times daily by intermittent infusion depending on renal function according to clinical guidelines. Over 4 days, multiple serum samples (median per patient, 29; in total, 1627) were obtained to determine total piperacillin concentrations using ultra-high-performance liquid chromatography/tandem mass spectrometry.
Results
A high heterogeneity of patient characteristics was observed (e.g., on day 1: creatinine clearance 2–233 mL/min and ten patients on RRT). Piperacillin trough levels showed inter-individual variation from 123 to >1785-fold on different study days. Each day, approximately 50 % and 60 % of the patients had piperacillin levels below the target ranges 1 and 2, respectively [defined for the calculated unbound piperacillin fraction according to the literature as 100 % time above MIC (100 %fT > MIC) (target range 1) and ≥ 50 %fT > 4 × MIC (target range 2); MIC = 16 mg/L]. Whereas only the minority of patients who received piperacillin-tazobactam three times daily (TID) reached target 1 (38 % on day 1), most patients who received piperacillin-tazobactam only twice daily (BID) because of severely impaired renal function reached this target (100 % on day 1). Patients with RRT had significant higher percentages of fT > MIC. Zero percent, 55 % and 100 % of patients without RRT who received antibiotics TID reached target 1 when creatinine clearance was > 65 mL/min, 30–65 mL/min and < 30 mL/min, respectively. In patients with causative strains only sensitive to piperacillin-tazobactam of all antibiotics given to the patient, piperacillin levels negatively correlated with CRP concentrations of day 4 (p < 0.05).
Conclusions
A dosage of 4.5 g piperacillin-tazobactam TID seems to be frequently insufficient in critically ill patients, and also in patients where renal function is mildly to moderately impaired. For these patients, prescription of 4.5 g piperacillin-tazobactam four times daily could be considered.
Trial registration
Clinicaltrials.gov NCT01793012 . Registered 24 January 2013.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果